Editas Medicine, Inc. (FRA:8EM)

Market Cap	163.51M +67.1%
Revenue (ttm)	39.53M -24.9%
Net Income	-170.32M
EPS	-2.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	213
Open	1.960
Previous Close	1.770
Day's Range	1.960 - 1.960
52-Week Range	0.827 - 3.823
Beta	n/a
RSI	41.70
Earnings Date	Mar 5, 2026

About Editas Medicine

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporate...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 246
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8EM

Financial Performance

In 2024, Editas Medicine's revenue was $32.31 million, a decrease of -58.64% compared to the previous year's $78.12 million. Losses were -$237.09 million, 54.7% more than in 2023.

Financial numbers in USD